Jobs at Olema Oncology

Olema Oncology

2 weeks ago

Director, Commercial Data Science

Data

In-OfficeExecutive$220,000+

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 weeks ago

Director, Commercial Data Science

Data

In-OfficeExecutive$220,000+

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 weeks ago

Director, Global Regulatory Affairs Strategy Lead

Legal

In-OfficeExecutive$230,000 - $250,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 weeks ago

Director, Global Regulatory Affairs - Strategy Lead

Legal

In-OfficeExecutive$230,000 - $250,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 weeks ago

Senior Director, Commercial Manufacturing and Operations

Operations

In-OfficeExecutive$260,000 - $285,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 weeks ago

Senior Director, Commercial Manufacturing and Operations

Operations

In-OfficeExecutive$260,000 - $285,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

This month

Medical Director, Clinical Development

Operations

In-OfficeExecutive$275,000 - $300,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Senior Manager, Clinical Supply Integration

Operations

In-OfficeLeadership

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Senior Manager, Clinical Supply Integration

Operations

In-OfficeLeadership

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Senior Director, Patient Safety Sciences

Operations

In-OfficeExecutive$270,000+

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Senior Director, Patient Safety Sciences

Operations

In-OfficeExecutive$270,000+

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Vice President of Information Technology

Operations

In-OfficeExecutive$335,000 - $365,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Director, Commercial Insights and Analytics

Data

In-OfficeExecutive$230,000 - $250,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

Last month

Director, Commercial Insights and Analytics

Data

In-OfficeExecutive$230,000 - $250,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Director, Compensation

Operations

In-OfficeExecutive$230,000 - $250,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Associate Director, Global Regulatory Affairs, Compliance and Project Management

Legal

In-OfficeExecutive$185,000 - $205,000

Boston, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Associate Director, Global Regulatory Affairs, Compliance and Project Management

Legal

In-OfficeExecutive$185,000 - $205,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Director, Compensation

Operations

In-OfficeExecutive$230,000 - $250,000

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Executive Assistant, supporting Chief Financial Officer

Finance

In-OfficeExecutive

San Francisco, United States

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Senior Director, National and Strategic Accounts

Operations

RemoteExecutive$250,000 - $275,000

Location not stated

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...

Olema Oncology

2 months ago

Senior Director, EU Regulatory Strategy

Legal

In-OfficeExecutive

Dublin, Ireland

Our lead product candidate, palazestrant, is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) currently in two pivotal Phase 3 clinical trials. We expect top-line data from...